Solasia Pharma K.K. Logo

Solasia Pharma K.K.

In-licenses and commercializes oncology treatments and supportive care products in Asia.

4597 | T

Overview

Corporate Details

ISIN(s):
JP3436500007
LEI:
Country:
Japan
Address:
港区芝公園二丁目11番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Solasia Pharma K.K. is a specialty pharmaceutical company focused on developing and commercializing innovative oncology products to address unmet medical needs in Japan and other Asian countries. The company's business model centers on in-licensing promising drug candidates and medical devices, primarily from the US and Europe. Its portfolio includes approved therapies for cancer treatment, such as Peripheral T-Cell Lymphoma, and supportive care solutions for managing treatment side effects like chemotherapy-induced nausea and vomiting (CINV) and oral mucositis. Solasia's development pipeline targets conditions including colorectal cancer and chemotherapy-induced peripheral neuropathy. The company leverages its small, expert team for quick and flexible decision-making to efficiently bring new treatments to market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 08:43
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-13 08:42
Interim Report
半期報告書-第18期(2025/01/01-2025/12/31)
Japanese 228.0 KB
2025-03-31 08:49
Registration Form
訂正有価証券届出書(組込方式)
Japanese 147.2 KB
2025-03-31 08:43
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2025-03-26 07:30
Registration Form
訂正有価証券届出書(組込方式)
Japanese 181.4 KB
2025-03-26 07:21
Governance Information
内部統制報告書-第17期(2024/01/01-2024/12/31)
Japanese 22.7 KB
2025-03-26 07:20
Registration Form
確認書
Japanese 8.1 KB
2025-03-26 07:19
Annual Report
有価証券報告書-第17期(2024/01/01-2024/12/31)
Japanese 1.1 MB
2025-03-24 07:37
Registration Form
有価証券届出書(組込方式)
Japanese 263.8 KB
2025-03-10 07:31
Regulatory News Service
臨時報告書
Japanese 19.5 KB
2024-08-14 08:43
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-08-14 08:42
Interim Report
半期報告書-第17期(2024/01/01-2024/12/31)
Japanese 238.4 KB
2024-05-15 08:42
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-15 08:40
Quarterly Report
四半期報告書-第17期第1四半期(2024/01/01-2024/03/31)
Japanese 219.9 KB
2024-03-26 07:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.8 KB

Automate Your Workflow. Get a real-time feed of all Solasia Pharma K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Solasia Pharma K.K.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Solasia Pharma K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.